“云”聚燕趙大地 共謀兒科未來
——記河北省引才引智國際學術交流兒童血液腫瘤高峰論壇

文 / 楊帆 劉曉梓 賈瀟瀟 冀鶴

在銀裝素裹的初冬時節，燕趙大地迎來了小兒血液腫瘤領域的學術盛會。 11月13日，河北省兒童醫院成功舉辦了“河北省兒科學會血液腫瘤專業委員會第一次學術會議暨河北省引才引智國際學術交流兒童血液腫瘤高峰論壇”。來自美國、加拿大等國家和北京、上海、廣州、南京等多名國內外知名兒科血液腫瘤專家、學者齊聚“云端”，同臺論道、積極分享，共同為提升遭受惡性血液、腫瘤疾病折磨的患兒治愈率和生存率、改善生存質量獻計獻策。河北省科學技術廳黨組副書記、副廳長兼河北省外國專家局局長郭玉明，河北省兒童醫院院長段國辰出席開幕式并講話。

郭玉明副廳長指出，河北省兒童醫院多年來，堅持與世界一流醫療科研院所交流合作，不僅為河北省培養了眾多學術造詣深、專業技術強的兒科知名專家，更做到了造福患兒、提升醫療技術水平的可喜成績。他表示，河北省科學技術廳、河北省外國專家局將繼續立足新發展階段，貫徹新發展理念，推動高質量發展，堅持把創新作為引領發展的第一動力，把人才作為支撐發展的第一資源，今后將一如既往地支持河北省兒童醫院的優質人才交流與合作，在科技創新、引智渠道、人才引進、項目合作及重大活動等方面給予大力支持，為關乎國家和民族未來的兒童健康事業發展大計作出應有的貢獻。

段國辰院長對出席此次學術盛會的領導、國內外專家和同仁表示熱烈歡迎和誠摯謝意。他表示，河北省兒童醫院兒童血液腫瘤專業發展迅速，學術水平逐步提高，不僅參與了國內多個協作組的項目研究，是多個國家級學術組織的委員單位，更是河北省白血病救治定點醫院組長單位，河北省血液病救治定點醫院，也是實體瘤協作組的牽頭單位；河北省兒童醫院通過與意大利、加拿大、美國、澳大利亞、日本等國家的先進醫療科研院所開展長期合作，兒童血液腫瘤疾病的診治技術走在了全省乃至全國的前列。目前，作為河北省唯一的兒童造血干細胞移植治療中心所屬單位，擁有6個移植倉，已完成58例兒童各類疾病造血干細胞移植治療，在造血干細胞移植方面也取得了驕人的成績。下一步，河北省兒童醫院內科住院樓投入使用，將再增加10個移植倉，血液腫瘤科床位將達到200張，努力打造成區域內和國內先進的血液腫瘤治療中心。

此次盛會學術氛圍嚴謹、交流氣氛融洽，國內外專家、學者圍繞當今學科領域熱點、難點話題積極闡述觀點、分享交流經驗。來自加拿大病童醫院的兒童腫瘤研究中心的首席研究員、加拿大皇家醫學院內科學院士Ronald Grant醫生，在小兒實體腫瘤的醫療和科研領域有著精深的造詣。他通過對加拿大病童醫院自2004年至今的10多年臨床治療經驗和回顧性數據總結得出，當前針對小兒復發性神經母細胞瘤多種新方法，已經向一線治療方案方向發展，CAR-T細胞免疫療法和以疫苗接種為基礎的治療可能即將問世，這將為改善預后、降低復發率和死亡率帶來新的曙光。

河北省兒童醫院院長段國辰出席河北省引才引智國際學術交流兒童血液腫瘤高峰論壇開幕式并講話

中外專家線上線下交流分享

來自美國洛杉磯兒童醫院血液疾病和骨髓移植中心的主任兼血液和骨髓移植（BMT）的臨床研究主任、美國兒科血液和骨髓移植協會主席Michael Pulsipher教授，在急性白血病尤其是急性淋巴細胞白血病（ALL）患者同種異體移植領域造詣頗深，曾榮獲美國國立衛生研究院（NIH）優秀獎，并作為6個國家多中心研究的主要或共同研究者。他介紹了經過多中心聯合研究、有著龐大科學數據佐證的最新研究結果，指出了CAR-T細胞治療在急性淋巴細胞白血病預測復發中面臨的挑戰，為未來細胞免疫療法的進一步探索指引了航向。

河北省兒童醫院是河北省最大的三級甲等綜合兒童醫院，在學科建設上始終秉持“聚四海之氣，借八方之力”的理念，堅定“走出去”“引進來”人才發展戰略，采取國內國際雙軌并進的方式聚才、用才，未來河北省兒童醫院將始終堅持醫院的公立定位，努力爭做兒童健康事業的先行者，搭建更多學科專業的合作交流平臺，繼續為救助患兒貢獻河北力量。

As the season changes, the fruitful golden autumn transfers into the early winter.An academic conference in the field of pediatric hematologic tumors was held in the Yanzhao area.On November 13th, Hebei Children’s Hospital successfully held the “The First Annual Conference of the Hematology-Oncology Committee of Hebei Pediatrics Association Cum Summit Forum for International Academic Exchange and New Progress in Children’s Hematology and Tumors in Hebei Province”.A number of wellknown pediatric hematological tumor experts and scholars from the United States, Canada and other countries,as well as domestic cities like Beijing, Shanghai, Guangzhou, Nanjing and so on,joined and shared their inspirational views of treatment and academic knowledge for enhancing the cure rate and survival rate of children suffering from malignant hematological tumor diseases,and improving the quality of life.Yuming Guo, deputy director of Science and Technology Department of Hebei Province, Director of Hebei Provincial Bureau of Foreign Experts Affairs, with Guochen Duan, the director of Hebei Children’s Hospital, attended the opening ceremony and made a significant speech online.

Deputy director Yuming Guo stressed that for many years, Hebei Children’s Hospital (HBCH) insists the communication and cooperation of world-class medical research institutes.Not only HBCH cultivate numerous well-known pediatric experts with academic attainments and professional skills, but also we achieved satisfactory results in enhancing the standard of medical technology and enabling the sick kids to touch the hope of life.He mentioned that the Science and Technology Department of Hebei Province and Hebei Provincial Bureau of Foreign Experts Affairs continually apply to the new developmental stage, implement the new development concept, promote high-quality development, insist the innovation as the main impetus, regard talents as the first supporter.Both institutions will support the communication and cooperation project of HBCH as always, such as technological innovations, exchanging channels, attracting talents, and so on.We will contribute to the development of Children’s health careers of the future of our nation and country.

President Guochen Duan expressed sincere thanks and a warm welcome to each director, specialist, and colleague who attended this summit forum.He mentioned that HBCH is one of the committee members of national academic organizations.The major pediatric hematologic tumor of HBCH represents a remarkable development.It is the leader unit of the designated hospital for leukemia treatment and a designated hospital for the treatment of hematological diseases in Hebei Province.Moreover, it is also the leading unit of pediatric solid tumor diagnosis and treatment in Hebei Province.The department of pediatric hematologic tumor participates in the national project research of several cooperative groups.The doctors’ abilities are enhanced gradually in the nations’ academic research area.By the long-term cooperation of advanced medical research institutes in Italy, Canada, America,and other countries, the diagnostic technique of pediatric hematologic tumor in HBCH reaches a senior level in Hebei province and China.

Nowadays, As the only pediatric hematopoietic stem cell transplantation treatment center in Hebei Province, Hebei children’s hospital of integrated traditional Chinese and western medicine has 6 transplant warehouses and has completed 58 cases of hematopoietic stem cell transplantation treatment for children with various diseases.That displays our hospital the extraordinary achievement in the field of hematopoietic stem cell transplantation treatment.To establish an advanced hematologic tumor treatment center in the Province and in China the inpatient building of the General Department of Internal Medicine of our hospital will be put into use.Another ten transplant warehouses will be added and the bed in the department of hematology and oncology will come up to 200 beds.

The academic atmosphere of this Summit Forum is strict and the atmosphere of exchanges is harmonious.Domestic and foreign experts and scholars actively expressed their views and shared exchange experiences around current focused and frustrated topics in pediatrics.Professor Ronald Grant who is a principal investigator of the pediatric oncology research center at the Hospital for Sick Children (SickKids) of Canada, and an academician of internal medicine of Canada Royal College.He has impressive attainments in the medical and scientific research fields in pediatric solid tumors.Since 2004, based on 15 years of Sickkids clinical treatment experiences and a retrospective database, he summarized a variety of methods focusing on pediatric recurrent neuroblastoma, which can be seen as an upfront therapy project.CAR-T cell immunotherapy and vaccination-based therapy may be forthcoming, which will present as a new expectation to improve prognosis, reduce recurrence and mortality.

Michael Pulsipher serves as Head of Transplantation and Cellular Therapy section and Endowed Chair of BMT Clinical Research, Los Angeles Children’s Hospital.Professor’s expertise is in acute leukemia.He especially has profound knowledge in the field of allogeneic transplantation for patients with acute lymphoblastic leukemia (ALL).He has won the USA National Institutes of Health (NIH) Excellence Award, and he is also the main or co-investigator of multi-center study in 6 countries.His report showed the latest research results that have been supported by huge scientific data and multi-center joint studies.He pointed out the challenges faced by CAR T cell therapy in predicting the recurrence of acute lymphoblastic leukemia.Furthermore, he pointed out a meaningful direction for further exploration of Cellular immunotherapy in the future.

As the largest Grade III, Class A general children’s hospital in Hebei Province, Hebei Children’s Hospital will always adhere to the concept of ‘Make use of all resources’ in discipline construction, firmly adhere to support the talent development strategy of ‘going out and bringing in’, and adopt the domestic and international dual-track approach to gather and use talents.Hebei Children’s Hospital will always adhere to the public positioning of the hospital, strive to be the pioneer of children’s health cause, build more disciplinary cooperation and exchange platform, actively participate in protecting children’s health cause, and continue to contribute to providing medical assistance.